Yondelis (trabectedin) stabilized a form of advanced mesothelioma that had progressed after earlier chemotherapy, according to a Phase 2 clinical trial in Italy. Researchers will…

Aduro Biotech has expanded its collaboration with Merck to include an additional Phase 2 trial to test a combination of Aduro’s immunotherapy, CRS-207, with Keytruda…

A Phase 3 British clinical trial will test whether the immune checkpoint inhibitor Opdivo (nivolumab) can help mesothelioma patients whose disease relapsed after platinum-based chemotherapy.…

Malignant Pleural Mesothelioma So, what is mesothelioma? Malignant pleural mesothelioma is a very aggressive and almost always fatal type of cancer caused by exposure to Asbestos.…

The U.S. Food and Drug Administration has granted Humanitarian Use Device (HUD) status to Novocure‘s Tumor Treating Fields (TTFields) for treating pleural mesothelioma. The designation…

The more mesothelioma tumor cells that express the mesothelin protein, the longer a patient is likely to live, according to a study. That finding is…

A study has tried to overcome the challenges in the diagnosis of patients with malignant pleural mesothelioma (MPM) through the detection of two biomarkers in pleural…

Whole exome sequencing of asbestos-induced mouse models of malignant mesothelioma (MM) is a genuine representation of human mesothelioma and is a valuable tool for further…